PREVIEW ASH 2026 — New Orleans, Dec 12–15: the abstracts hematologists are watching, top voices and trial buzz See the ASH 2026 preview →
KOL Pulse Insights Blog

Oncology KOL Intelligence, decoded.

Key opinion leader trends, clinical-trial commentary, conference recaps, and AI-native intelligence on the physicians shaping oncology practice — straight from the social conversation.

1Articles
WeeklyNew insights
500+Verified oncologists tracked
0 articles · All topics
From ASCO24 Hype to FDA CRL Reality: Why Did Summit's First Ivonescimab Submission Fail?
Nov 15, 2026, 1:27:15 PM Brian Shields

From ASCO24 Hype to FDA CRL Reality: Why Did Summit's First Ivonescimab Submission Fail?

The FDA issued a CRL for ivonescimab plus chemo in EGFR-mutant NSCLC after HARMONi missed statistical significance on OS (HR 0.79, P=0.057). Slides from WCLC 20…

lung cancernsclcegfrmut

Track the KOLs shaping oncology

KOL Pulse turns the oncology social conversation into AI-native intelligence. See it in action.

Book a Demo Back to Homepage